Clinical trials: Cardiovascular and Cerebrovascular Diseases
Fabry Disease, Chronic Kidney Disease, Stage IV (Severe)
Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme
This study was designed to determine appropriate treatment with Fabrazyme at a biweekly dose of either 1 mg/kg or 3 mg/kg in a population of patients with severe renal disease burden.
- Trial name
- NCT00837824
- Testing
- Fabrazyme (agalsidase beta)
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Genzyme, a Sanofi Company
Coronary Artery Bypass Grafting, Postoperative Atrial Fibrilation
Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation
In this open-label, prospective, randomized pilot study, patients who develop atrial fibrillation after isolated coronary artery bypass grafting surgery will be identified.
- Conditions
- Coronary Artery Bypass Grafting, Postoperative Atrial Fibrilation, Stroke, Systemic Embolism
- Trial name
- NCT02889562
- Testing
- Apixaban, Warfarin
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Sanford Health
Non-valvular Atrial Fibrillation
Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data
The objective of this study is to investigate safety and effectiveness of apixaban compared to warfarin in very elderly patients with Non-valvular atrial fibrillation (NVAF).
- Trial name
- NCT05438888
- Testing
- Warfarin, Apixaban
- Where
- Japan
- Volunteers
- 77,814 people
- Sponsor
- Pfizer
Aphasia, Primary Progressive Aphasia
Circuitry Assessment and Reinforcement Training Effects on Recovery
This study investigates if electroencephalography (EEG) neurofeedback training is more beneficial than sham feedback training for the improvement of communication, anxiety, and sleep quality in individuals with aphasia.
- Conditions
- Aphasia, Primary Progressive Aphasia, Stroke
- Trial name
- CARTER (NCT04290988)
- Testing
- EEG Neurofeedback
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Johns Hopkins University
Cerebrovascular Disorders
HYPEROXIA Responses and ROS
30 participants (15 males and 15 females) who are ≥18 - ≤ 40 years old and considered healthy will be enrolled into this study to test the role of reactive oxygen species (ROS) in regulating cerebral blood flow (CBF).
- Trial name
- NCT05958303
- Testing
- Antioxidant Cocktail
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Stroke
CLOTBUST Hands-Free: A Phase I/II Pilot Safety Trial
The purpose of CLOTBUST-HF is to determine the safety of a novel, external Hands-Free transcranial Doppler (TCD) ultrasound system in healthy volunteers and ischemic stroke patients.
- Trial name
- CLOTBUST-HF (NCT01240356)
- Testing
- 2-MHz transcranial Doppler ultrasound, 2-MHz transcranial Doppler ultrasound insonation
- Where
- 2 sites in United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Stroke, Cerebrovascular Accident
Spinal Plasticity to Enhance Motor Retraining After Stroke
The objective of this project is to study the effects of an emerging noninvasive neuromodulation strategy in human stroke survivors with movement-related disability.
- Conditions
- Stroke, Cerebrovascular Accident, Hemiparesis
- Trial name
- NCT03645122
- Testing
- Paired corticospinal-motoneuronal stimulation (PCMS)
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Ischemic Attack, Transient
Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial
A transient ischemic attack (TIA) is a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction. An ischemic stroke is a cerebral infarction.
- Trial name
- POINT (NCT00991029)
- Testing
- Clopidogrel
- Where
- 210 sites in United States, Australia and 8 more
- Volunteers
- 4,881 people
- Sponsor
- University of California, San Francisco
Intracranial Aneurysm, Subarachnoid Hemorrhage
CorPath® GRX Neuro Study
The primary objective of this study is to evaluate the effectiveness and safety of robotic-assisted endovascular embolization procedures compared to objective performance criteria for traditional, manual operation based on the…
- Conditions
- Intracranial Aneurysm, Subarachnoid Hemorrhage, Headache
- Trial name
- NCT04236856
- Testing
- Robotic Endovascular Procedure
- Where
- 10 sites in Australia, Austria and 4 more
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Siemens Healthineers Endovascular Robotics, Inc.
Bleeding Disorder, Stroke, Ischemic
XIENCE 28 Global Study
XIENCE 28 Global Study is a prospective, single arm, multi-center, open label, non-randomized trial to further evaluate the safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of…
- Conditions
- Bleeding Disorder, Stroke, Ischemic, Stroke Hemorrhagic, Hematological Disease
- Trial name
- NCT03355742
- Testing
- XIENCE, DAPT
- Where
- 52 sites in Austria, Belgium and 11 more
- Volunteers
- 963 people
- Sponsor
- Abbott Medical Devices
Carotid Artery Diseases, Stroke
Safety and Performance Evaluation of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting
The purpose of this study is to compare the safety and performance of WIRION™ EPD in patients undergoing carotid artery stenting to a performance goal based on an analysis of the results of previous US IDE carotid stenting with…
- Trial name
- WISE (NCT01783639)
- Testing
- Carotid Artery Stent
- Where
- 10 sites in Belgium, Germany and 1 more
- Volunteers
- 120 people
- Sponsor
- Gardia Medical
Aneurysmal Subarachnoid Hemorrhage, Cerebral Vasospasm
Acetaminophen in aSAH to Inhibit Lipid Peroxidation and Cerebral Vasospasm
The objective of this study is to determine whether acetaminophen (APAP), N-acetylcysteine (NAC), and APAP in combination with NAC will inhibit lipid peroxidation in aneurysmal subarachnoid hemorrhage (aSAH), utilizing F2-IsoPs…
- Trial name
- NCT00585559
- Testing
- APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly, APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Vanderbilt University Medical Center
Cardiovascular Disease
Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine
SEARCH is a randomised, double-blind, multi-centre United Kingdom (UK) trial of 12,064 patients with myocardial infarction (MI) prior to study entry which aims to demonstrate whether a more intensive cholesterol lowering regimen…
- Trial name
- SEARCH (NCT00124072)
- Testing
- Simvastatin 20 mg daily, Folic acid 2 mg + vitamin B12 1 mg daily, Simvastatin 80 mg daily
- Where
- United Kingdom
- Volunteers
- 12,064 people
- Sponsor
- University of Oxford
Cerebrovascular Accident
Stroke Gait Rehabilitation Using Functional Electrical Stimulation
The study is a prospective interventional study to assess the changes in corticospinal excitability and spinal reflex excitability of in response to rehabilitative strategies and protocols that are commonly used during physical…
- Trial name
- NCT01668602
- Testing
- Fast Walking with Fast Functional Electrical Stimulation (FES) Training, Fast Walking
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Emory University
Fabry Disease
Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease
The primary objective of this study was to compare the effect of migalastat (123 milligrams [mg] of migalastat [equivalent to 150 mg of migalastat hydrochloride]) (migalastat) versus placebo on kidney globotriaosylceramide (GL-3).
- Trial name
- NCT00925301
- Testing
- migalastat hydrochloride
- Where
- 28 sites in United States, Argentina and 11 more
- Volunteers
- 67 people
- Sponsor
- Amicus Therapeutics
Giant Cell Arteritis
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
Sirukumab is a fully human anti-interleukin-6 (IL-6) immunoglobulin G1-kappa with a high affinity and specificity for binding to the human IL-6 molecule that may have therapeutic benefit in the treatment of giant cell arteritis…
- Trial name
- NCT02531633
- Testing
- Sirukumab, Prednisone
- Where
- 63 sites in United States, Australia and 11 more
- Volunteers
- 161 people
- Sponsor
- GlaxoSmithKline
Stroke Hemorrhagic, Depression
Poststroke Depression in Hemorrhagic Stroke
A double-blinded placebo-controlled randomized trial to evaluate the effect of preventative treatment of depression in survivors of aneurysmal subarachnoid hemorrhage (aSAH), a type of stroke.
- Trial name
- NCT03826875
- Testing
- Fluoxetine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Washington
Fabry Disease
Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study
Study to evaluate the long-term safety, tolerability, and pharmacodynamics (PD) of migalastat hydrochloride (HCl) (migalastat) in participants with Fabry disease
- Trial name
- NCT00526071
- Testing
- migalastat HCl
- Where
- 8 sites in United States, Australia and 3 more
- Volunteers
- 23 people
- Sponsor
- Amicus Therapeutics
Intracranial Hemorrhages
Validation of Falls Decision Rule to Exclude Intracranial Bleeding in Geriatric Fall Patients
Although falls are the most important cause of intracranial hemorrhage in the population over 65, studies have shown that bleeding occurs in only 5% of geriatric patients who fall.
- Trial name
- NCT06525727
- Testing
- Falls Decision Rule
- Where
- Turkey (Türkiye)
- Volunteers
- 800 people
- Sponsor
- Marmara University
Depression, Major Depressive Disorder
eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients
The objective of this randomized controlled trial is to evaluate whether the investigators modernized IMPACT intervention for depression (eIMPACT), delivered before the onset of cardiovascular disease (CVD), reduces the risk of…
- Conditions
- Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms
- Trial name
- NCT02458690
- Testing
- Beating the Blues (BtB), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications
- Where
- United States
- Volunteers
- 216 people
- Sponsor
- Indiana University